© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep
Hikma Pharmaceuticals PLC (HKMPY) stock remained unchanged at $43.18 a share on OTC. The stock opened at $43.18, fluctuating between $43.18 to $43.18 during the session.
| Filing Date | Accepted Date | |
|---|---|---|
| Filing Date | Accepted Date | |
|---|---|---|
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 03, 2026 | 43.18 | 43.18 | 43.18 | 43.18 | 100 |
| Sep 01, 2026 | 43.68 | 43.68 | 43.46 | 43.46 | 400 |
| Aug 27, 2026 | 44.07 | 44.07 | 44.07 | 44.07 | 100 |
| Aug 25, 2026 | 43.88 | 43.88 | 43.88 | 43.88 | 217 |
| Aug 24, 2026 | 43.94 | 43.94 | 43.94 | 43.94 | 108 |
| Aug 18, 2026 | 44.60 | 44.60 | 44.60 | 44.60 | 349 |
| Aug 14, 2026 | 45.36 | 45.36 | 45.36 | 45.36 | 190 |
| Aug 12, 2026 | 45.59 | 45.84 | 45.59 | 45.84 | 4 |
| Aug 10, 2026 | 44.18 | 44.18 | 44.18 | 44.18 | 1 |
| Aug 06, 2026 | 46.55 | 47.00 | 45.92 | 46.21 | 5.03K |
| Aug 05, 2026 | 43.49 | 43.49 | 43.49 | 43.49 | 2 |
| Jul 29, 2026 | 44.37 | 44.37 | 44.37 | 44.37 | 1 |
| Jul 28, 2026 | 42.98 | 44.11 | 42.98 | 43.50 | 5.01K |
| Jul 27, 2026 | 41.76 | 41.76 | 41.76 | 41.76 | 249 |
| Jul 23, 2026 | 41.41 | 41.41 | 41.27 | 41.27 | 399 |
| Jul 22, 2026 | 42.72 | 42.81 | 41.96 | 42.02 | 7.07K |
| Jul 21, 2026 | 41.23 | 41.23 | 41.23 | 41.23 | 101 |
| Jul 20, 2026 | 41.42 | 41.42 | 41.18 | 41.18 | 302 |
| Jul 16, 2026 | 42.34 | 42.34 | 42.00 | 42.00 | 227 |
| Jul 15, 2026 | 40.55 | 40.55 | 40.55 | 40.55 | 101 |
Hikma Pharmaceuticals PLC is a global pharmaceutical company that specializes in the development, production, commercialization, and distribution of a wide array of generic, branded, and in-licensed medicines. These pharmaceuticals are provided in various final dosage forms, including solid, semi-solid, liquid, and injectable formats. The company's business activities are organized into three core divisions: Injectables, Generics, and Branded products. The Injectables division primarily supplies generic injectable medications for hospital use. Its Generics segment focuses on offering oral and other non-injectable generic formulations to the retail market. The Branded segment, conversely, delivers branded generic drugs and products licensed from third parties to both retail consumers and hospitals. Hikma's product portfolio addresses numerous therapeutic areas, such as anti-infectives, cardiovascular health, central nervous system conditions, diabetes, oncology, pain management, and respiratory illnesses. The company maintains a substantial international footprint, operating throughout the United Kingdom, the United States, the Middle East, North Africa, Europe, and other global markets. Founded in 1978, Hikma Pharmaceuticals PLC has its headquarters in London, UK.
| Employees | 9400 |
| Beta | 0.66 |
| Sales or Revenue | $2.88B |
| 5Y Sales Change% | 0.497% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |